Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of “Buy” by Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have received a consensus rating of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat reports. Nine analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $136.50.

A number of analysts have recently weighed in on the stock. Bank of America decreased their price target on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. The Goldman Sachs Group decreased their price target on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Guggenheim restated a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Cantor Fitzgerald assumed coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an “overweight” rating on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th.

Vaxcyte Stock Down 4.7%

Shares of NASDAQ:PCVX opened at $35.44 on Thursday. Vaxcyte has a 52-week low of $27.66 and a 52-week high of $121.06. The company has a 50 day moving average of $32.54 and a two-hundred day moving average of $64.03. The company has a market capitalization of $4.57 billion, a price-to-earnings ratio of -7.70 and a beta of 1.20.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the prior year, the business earned ($0.85) EPS. On average, equities analysts anticipate that Vaxcyte will post -4.21 earnings per share for the current year.

Institutional Investors Weigh In On Vaxcyte

Hedge funds have recently added to or reduced their stakes in the stock. Whipplewood Advisors LLC bought a new stake in Vaxcyte in the fourth quarter valued at $28,000. Smartleaf Asset Management LLC lifted its stake in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI bought a new stake in Vaxcyte in the fourth quarter valued at $41,000. Blue Trust Inc. lifted its stake in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after buying an additional 371 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after buying an additional 775 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.